Modality
Multispecific
MOA
HER2
Target
B7-H3
Pathway
Incretin
BCC
Development Pipeline
Preclinical
May 2022
→ May 2024
PreclinicalCurrent
NCT08838344
1,138 pts·BCC
2024-05→TBD·Active
NCT06831584
841 pts·BCC
2022-05→TBD·Completed
1,979 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-06-253mo awayPDUFA· BCC
Trial Timeline
Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3
Preclinical
Complet…
Preclinical
Active
Catalysts
PDUFA
2026-06-25 · 3mo away
BCC
ActiveCompleted|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08838344 | Preclinical | BCC | Active | 1138 | SeizFreq |
| NCT06831584 | Preclinical | BCC | Completed | 841 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7809 | Pfizer | Phase 1 | DLL3 | |
| LLY-8903 | Eli Lilly | Preclinical | CD47 | |
| LLY-4358 | Eli Lilly | Phase 3 | B7-H3 | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| SNY-7254 | Sanofi | Phase 2 | CFTR | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| Datobrutinib | Sanofi | Phase 3 | Aβ | |
| SNY-9073 | Sanofi | Phase 2 | B7-H3 | |
| NVO-7840 | Novo Nordisk | Phase 2/3 | B7-H3 |